Arcturus to prioritize mRNA therapeutics in bid to boost rare disease programs

Arcturus Therapeutics is doubling down on mRNA technology. The biotech said Monday that it's prioritizing its experimental self-amplifying mRNA drugs, with a focus on programs for cystic fibrosis and a rare ...